anonymous
Guest
anonymous
Guest
Was he really? Well, Marion may not have the eye for quality. The business is suffering due to both their ineptitude. The outlook for the regeneron bispecific oncology portfolio looks pretty bad. Not sure who's fault that is but sure as hell doesn't help when our inline product has been puttering along since getting approved in lung cancer. Is that L&G's fault, Marion's or Justin's? Maybe a combination but we wouldn't be asking these questions if we an effective commercial leader was responsible for oncology. JH sure isn't and this business will never be what it can to get the entire field fired up to bring the results we need. Are we at fault? Maybe we also have some blame to carry. But the team in sleepy hollow is AA baseball for the Cleveland whatever the hell they call themselves.